Hints and tips:
Related Special Reports
...Microsoft expects its partnership with Brookfield to help finance large new wind and solar farms to be built between 2026 and 2030, beginning in the US and Europe....
...Clean energy sources such as wind and solar, backed by storage batteries, have plummeted in cost and gained electricity market share....
...The New York-based pharma group has acquired four companies — Arena, ReViral, Biohaven and Global Blood Therapeutics — that it expects will contribute about $10bn in revenues in 2030....
...Last year the agency invested €320mn in de-risking deals on the continent, and has supported start-ups including Spark, an off-grid solar company....
...A flood of Chinese-produced solar panels is driving prices to record lows in the US, a boon for renewable energy developers but a threat to solar manufacturers trying to create a domestic supply chain for...
...Earlier this month, 1Komma5 announced that it had acquired Australian solar provider Arkana Energy Group. Schröder said 1Komma5 was now the third-largest solar provider in Australia....
...First Solar, an Arizona-based clean energy equipment maker, has $1.8bn in overall balance sheet cash....
...Not much is said any more about the status of the Solar Roof, nor Tesla’s solar efforts more generally....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Increasingly the US asset manager he heads is the star around which the digital assets solar system orbits....
...It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
Carmaker’s board under pressure after Delaware judge rules billionaire CEO has to forfeit largest ever incentive package
...“It’s not just large-scale wind and solar [assets] but different ways of supporting the transition, such as battery energy storage....
...Power Points US solar manufacturers in ‘dire situation’ as imports soar Commodities house Mercuria parts with global head of trading Opinion: Our stressed-out power grids need help Energy Source is written...
...A different Delaware judge in 2022 had ruled that Musk did not improperly influence the price of a merger between Tesla and solar panel company SolarCity, two companies in the entrepreneur’s portfolio that...
...molnupiravir or Paxlovid will [still] be effective, now that most people have been either vaccinated or infected,” said Andy Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics...
...to rescue Farfetch Regulators even out the antitrust score Global regulators had been on a losing streak lately, with back-to-back losses including Amgen’s $28bn takeover of fellow drugmaker Horizon Therapeutics...
...The term was coined by Morgan Stanley analyst Adam Jonas, who wrote in December 2021: What do EVs, autonomy, Dojo, energy storage, solar, Giga-press, humanoids, rockets, sats, tunnels, and brain implants...
...Monday’s acquisition by Novartis of Seattle-based biotech firm Chinook Therapeutics for up to $3.5bn is a case in point....
...The researchers plan to make 381,000 of the most promising structures available to fellow scientists to make and test their viability in fields from solar cells to superconductors....
...Banks Renewables, part of the family-owned Banks Group, owns operational onshore wind farms in northern England and Scotland, and also has a large portfolio of onshore wind, solar and battery assets in development...
...The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to...
...Andrew Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics department, said the drug also had potential side effects for pregnant women....
...Massachusetts-based Luminopia, which creates therapeutic visual stimuli, raised $16mn in late June....
...regulators have warned that “rampant consolidation” in the pharmaceuticals industry is pushing up prices for patients as the Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics...
International Edition